EUCTR2009-011172-30-SE进行中（未招募）不适用
A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S DISEASE PATIENTS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females (of non-childbearing potential) ages =50 years of age at screening
- •2. Diagnosis of probable AD, consistent with criteria from both:
- •- NINCDS-Alzheimer’s Disease and Related Disorders Association (ADRDA);
- •- DSM-IV-TR
- •3. The subject must have a reliable caregiver with contact at least 3 times per week (combination of face to face visits and telephone contact acceptable) who will facilitate the subject’s full participation in the study. Caregivers must have sufficient subject interaction to be able to provide meaningful input into the DAD
- •4. Subjects and caregivers must be able to read, write, and speak the language in which psychometric tests are provided with acceptable visual and auditory acuity
- •5. MMSE score of 16–26 inclusive at screening
- •6. Rosen-Modified Hachinski Ischemia Score =4
- •7. Subjects must be on a stable dose of background cholinesterase inhibitor and/or memantine at least 60 days prior to dosing, with the following caveats: background cholinesterase inhibitor and/or memantine therapy is not required if the subject had previously demonstrated a lack of toleration
- •8. Subjects must weigh 35-100 kg
- •9. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) and caregiver have been informed of all pertinent aspects of the trial. Subject must be able to provide assent and assent may be re-evaluated during the study at regular intervals
- •10. Subjects and caregivers are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures
- •11. Diabetic subjects may be included provided that their disease and serum glucose values are controlled and being actively managed, as assessed by the PI using a fasting blood sugar and/or HgA1C (per the PI’s medical judgment for diabetics)
- •12. In general good health, in the opinion of the Principal Investigator (PI), based on medical history, physical examination, vital signs, 12-lead ECG, and laboratory values, including hematology and chemistry values
- •13. Cohort M only - Subjects receiving amyloid imaging (PET) must have measurable amyloid burden on the screening brain PET scan with radiotracer retention in the range expected for AD patients. This will be defined as 3 of the 5 target regions (anterior cingulate, posterior cingulate, frontal cortex, temporal cortex, and parietal cortex) having a ratio of target region radioactivity (kBq/ml) over reference region radioactivity (cerebellar grey matter) >1.5. Subjects that do not have measurable amyloid burden will be excluded
- •14. Cohort M only - Subjects with a previous brain PET scan may be eligible to enter the study provided that the subject does not exceed the required local and/or national radiation exposure requirements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Known presenilin mutations
- •2. Diagnosis or history of other possible cause for or significant contributor to dementia
- •3. Diagnosis or history of cerebrovascular disease, severe carotid stenosis, cerebral hemorrhage, intracranial tumor, subarachnoid hemorrhage, or subdural hematoma that could either contribute to the subject’s current cognitive or functional status, impair their ability to fully participate in the trial or that may impact their status during the two year trial
- •4. Specific exclusionary brain MRI findings that could either contribute to the subject’s current cognitive or functional decline, impair their ability to fully participate in the trial or that may impact their status during the one year course of the trial including:
- •- Cortical infarct;
- •- >2 micro hemorrhages;
- •- Strategically located subcortical gray matter infarct
- •- Multiple (2 or more) white matter lacunes
- •5. History or diagnosis of an underlying hematological disorder causing easy bruising
- •6. History or symptoms of a serious autoimmune disorder
- •7. History of cancer within the last 5 years
- •8. History of clinically significant cardiac arrhythmia or heart block
- •9. History or diagnosis of clinically significant ischemic heart disease, congestive heart failure, cardiomyopathy, myocarditis, left ventricular hypertrophy, valvular heart disease
- •10. History of clinically significant renal disease
- •11. Subjects with uncontrolled hypertension even with therapeutic intervention
- •(=170/100)
- •13. History of clinically significant syncope, seizure, head trauma, or clinically significant unexplained loss of consciousness within the last 5 years
- •14. A diagnosis of major depressive disorder or other psychiatric illness as the primary diagnosis
- •16. Known history of alcohol or drug abuse within 5 years prior to dosing or a positive result as a result of illicit drugs on the drug screening test
- •17. History of hospital admission within the last 2 years for asthma, chronic obstructive pulmonary disease, or other chronic respiratory conditions
- •18. Known positive HIV status
- •19. Subjects who reside in a nursing home or that are inpatients in a hospital; assisted living facilities are permitted
- •20. Subjects who are unable to participate in a successful baseline lumbar puncture and sample obtained
- •21. Subjects on anticoagulants or aspirin doses >325 mg/day within the last month. Plavix® (clopidogrel bisulfate) or aspirin may be discontinued per the PI’s medical judgment 3 -7 days prior to lumbar puncture
- •22. Previous exposure to investigational or non-investigational immune- or biologic therapies for Alzheimer’s disease such as anti-A ß antibodies, or ß- or gamma-secretase inhibitors.
- •23. Known allergy or sensitivity to gadolinium (or similar) contrast agents or PIB ligand that will affect the subject’s participation in this clinical trial or any device/implant/condition that would contraindicate a brain MRI or PET scan.
- •24. History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody or IgG-fusion protein.
- •25. Medications that may negatively affect cognitive function
- •26. Subjects cannot participate in other clinical drug trials for the duration of the study or donate blood within 8 weeks prior to the first infusion and for 6 months after the last administration of study drug.
- •27. History of sensitivity to heparin or heparin-induced thrombocytopenia.
- •28. Clinically significant laboratory abnormalities
- •29. Screening creatinine clearance of <30
研究者
相似试验
进行中（未招募）
不适用
Phase 2 clinical trial to investigate the safety and how both PF-04937319 and sitigliptin work to control blood sugar, inadequately controlled on metformin, in people who have been diagnosed with Type 2 Diabetes within the past 5 years.EUCTR2011-004002-25-HUPfizer Inc., 235 East 42nd Street, New York, NY 10017300
进行中（未招募）
不适用
PHASE 2 CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND GLIMEPIRIDE IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIType 2 Diabetes Mellitus (T2DM)MedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-005206-30-BGPfizer Inc., 235 East 42nd Street, New York, NY 10017300
进行中（未招募）
不适用
Phase 2 clinical trial to investigate the safety and how both PF-04937319 and sitigliptin work to control blood sugar, inadequately controlled on metformin, in people who have been diagnosed with Type 2 Diabetes within the past 5 years.EUCTR2011-004002-25-SKPfizer Inc., 235 East 42nd Street, New York, NY 10017300
进行中（未招募）
不适用
PHASE 2 CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND GLIMEPIRIDE IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIEUCTR2011-005206-30-SKPfizer Inc., 235 East 42nd Street, New York, NY 10017300
进行中（未招募）
不适用
PHASE 2 CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND GLIMEPIRIDE IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIEUCTR2011-005206-30-HUPfizer Inc., 235 East 42nd Street, New York, NY 10017300